Genetic screening tests are an opportunity for timely detection and prevention which can identify women with high risk of breast and ovarian cancer for whom special screening and monitoring can be a preventive and even a life-saving measure. Veritas Genetics’ myBRCA, available at www.veritasgenetics.com, identifies harmful mutations in BRCA1 and BRCA2 genes which are among the most studied in the human genome. Over 20 years of experience and clinical evidence show that harmful mutations in these genes represent an 80% lifetime risk for breast cancer and up to 40% for ovarian cancer. (Source: Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2013 Sep 26]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: NCBI)